Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11902437 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL14550059 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL1839151 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL1019425 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL4209759 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL34467094 | 0.87 | MAPT (0.53) | SLC9A1FFAR1MAPTGAAHPGD | |
| SCHEMBL16232154 | 0.84 | SLC9A1 (0.60) | SLC9A1HRH3KDM1ASIGMAR1MAPT | |
| SCHEMBL17189659 | 0.84 | SLC9A1 (0.65) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL13976000 | 0.84 | SLC9A1 (0.65) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL12765396 | 0.84 | SLC9A1 (0.60) | SLC9A1HRH3KDM1ASIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4617264-A1 | ISOINDOLINONE DERIVATIVE HAVING ARYLCYCLOALKYLAMIDE STRUCTURE, AND USE THEREOF | Oncord Bio Inc (KR) | 2025-09-17 | — | — | EP | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025006568-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024101763-A1 | ISOINDOLINONE DERIVATIVE HAVING ARYLCYCLOALKYLAMIDE STRUCTURE, AND USE THEREOF | 주식회사 온코드바이오 | 2024-05-16 | — | — | WO | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023125846-A1 | COMPOUND FOR PREVENTING AND TREATING CORONAVIRUS INFECTION, CONJUGATE THEREOF AND METHOD THEREFOR | 苏州爱科百发生物医药技术有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20220025424-A1 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE AMINOCYCLOPROPANES | IMAGO BIOSCIENCES, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20180273476-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | MERCK PATENT GMBH (DE) | 2018-09-27 | — | — | US | disclosed |
| US-9914702-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2018-03-13 | — | — | US | disclosed |
| EP-1386909-A1 | Cyclopropane amines | AstraZeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1386921-A1 | Intermediates | AstraZeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1386917-A1 | Intermediates | AstraZeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| EP-0996621-B1 | TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030144305-A1 | Novel compounds | ASTRAZENECA AB | 2003-07-31 | — | — | US | disclosed |
| US-6525060-B1 | P2T (P2YADP or P2TAC) receptor antagonists; anticoagulant, antithrombotic | ASTRAZENECA UK LIMITED (GB) | 2003-02-25 | — | — | US | disclosed |
| EP-1056749-B1 | NOVEL TRIAZOLO(4,5-d)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2003-02-19 | — | — | EP | disclosed |
| US-6369064-B1 | MYOCARDIAL INFARCTION AND UNSTABLE ANGINA; P2T-RECEPTOR ANTAGONISTS; ANTITHROMBOTIC AGENTS; 7-(SUBSTITUTED AMINO) -5-(THIO)-3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDIN-3-YL) -CYCLOPENTANECARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-04-09 | — | — | US | disclosed |
| US-6251910-B1 | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists | ASTRAZENECA UK LIMITED (GB) | 2001-06-26 | — | — | US | disclosed |
| US-5506237-A | PROLYL-ENDOPEPTIDASE INHIBITOR; USEFUL FOR TREATING OR PREVENTING MEMORY LOSS DUE TO AGING, ANXIETY AND DEPRESSION | ADIR ET COMPAGNIE (FR) | 1996-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273476-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | KCNA3, KCNH3, KCNK3 | SLC9A1 226/4885FFAR1 2942/4885HRH3 176/4885 |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DUSP2, MKNK2, DUSP22 | SLC9A1 4335/4885FFAR1 4314/4885HRH3 2642/4885 |
| US-20030144305-A1 | Novel compounds | DPYD, TYMP, NUDT15 | SLC9A1 4625/4885FFAR1 4622/4885HRH3 1227/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | SLC9A1 3240/4885FFAR1 4334/4885HRH3 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.